By FieldPulse Staff · March 17, 2026
Tags: layoffs, strategy
Gossamer Bio cuts 48% of staff after Phase 3 PAH drug seralutinib misses primary endpoint. 77 employees laid off; company now exploring strategic options.
Gossamer Bio announced on March 17, 2026 that it would eliminate 77 employees — approximately 48% of its total workforce — after its Phase 3 PROSERA trial of seralutinib in pulmonary arterial hypertension (PAH) missed its primary endpoint. The trial showed a placebo-adjusted 13.3-meter improvement in six-minute walk distance, falling short of the statistical threshold needed for approval. The company is now conserving cash and exploring strategic options, including a potential asset sale or partnership. Gossamer previously raised the Phase 3 readout as a potential near-term catalyst. The failu